Celltrion boasts worldwide tech lead in biosimilars

South Korea has more biosimilar firepower than just consumer electronics convert Samsung. Celltrion, under the leadership of Seo Jung-jin, is a biosimilars "front-runner," says the CEO. Celltrion has "about four to five years" of a technology lead over rivals, he says. "There will be no serious competitor by 2015, in which period the industry's capacity will be short of demand," Seo says. Story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.